<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13G
(RULE 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b)(c) AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO 13d-2(b)
(AMENDMENT NO. __)(1)
GENOME THERAPEUTICS CORP.
-------------------------
(Name of Issuer)
COMMON STOCK
------------
(Title of Class of Securities)
372430 10 8
-----------
(CUSIP Number)
DECEMBER 1, 2000
----------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
|_| Rule 13d-1(b)
|X| Rule 13d-1(c)
|_| Rule 13d-1(d)
--------
(1) The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 or otherwise subject to the liabilities of that section of the Act but
shall be subject to all other provisions of the Act (however, SEE the NOTES).
<PAGE>
CUSIP NO. 372430 10 8 13G PAGE 2 of 8 PAGES
--------- ---------------------------------------------------------------------
1 NAME OF REPORTING PERSON:
BIOTECHNOLOGY VALUE FUND, L.P.
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):
--------- ---------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) |X| (b) |_|
--------- ----------------------------------------------------------------------
3 SEC USE ONLY
--------- ----------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
DELAWARE
--------- ---------------- ----- -----------------------------------------------
NUMBER SOLE VOTING POWER
OF 5 0
SHARES -----------------------------------------------
BENEFICIALLY SHARED VOTING POWER
OWNED BY EACH 6 495,100
REPORTING -----------------------------------------------
PERSON SOLE DISPOSITIVE POWER
WITH 7 0
-----------------------------------------------
SHARED DISPOSITIVE POWER
8 495,100
--------- ----------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
495,100
--------- ----------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES* |_|
--------- ----------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
2.2%
--------- ----------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
PN
--------- ----------------------------------------------------------------------
* SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
CUSIP NO. 372430 10 8 13G PAGE 3 of 8 PAGES
--------- ---------------------------------------------------------------------
1 NAME OF REPORTING PERSON:
BIOTECHNOLOGY VALUE FUND II, L.P.
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):
--------- ---------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) |X| (b) |_|
--------- ----------------------------------------------------------------------
3 SEC USE ONLY
--------- ----------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
DELAWARE
--------- ---------------- ----- -----------------------------------------------
NUMBER SOLE VOTING POWER
OF 5 0
SHARES -----------------------------------------------
BENEFICIALLY SHARED VOTING POWER
OWNED BY EACH 6 908,800
REPORTING -----------------------------------------------
PERSON SOLE DISPOSITIVE POWER
WITH 7 0
-----------------------------------------------
SHARED DISPOSITIVE POWER
8 908,800
--------- ----------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
908,800
--------- ----------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES* |_|
--------- ----------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
4.1%
--------- ----------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
PN
--------- ----------------------------------------------------------------------
* SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
CUSIP NO. 372430 10 8 13G PAGE 4 of 8 PAGES
--------- ---------------------------------------------------------------------
1 NAME OF REPORTING PERSON:
BVF PARTNERS L.P.
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):
--------- ---------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) |X| (b) |_|
--------- ----------------------------------------------------------------------
3 SEC USE ONLY
--------- ----------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
DELAWARE
--------- ---------------- ----- -----------------------------------------------
NUMBER SOLE VOTING POWER
OF 5 0
SHARES -----------------------------------------------
BENEFICIALLY SHARED VOTING POWER
OWNED BY EACH 6 1,451,400
REPORTING -----------------------------------------------
PERSON SOLE DISPOSITIVE POWER
WITH 7 0
-----------------------------------------------
SHARED DISPOSITIVE POWER
8 1,451,400
--------- ----------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,451,400
--------- ----------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES* |_|
--------- ----------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
6.5%
--------- ----------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
PN
--------- ----------------------------------------------------------------------
* SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
CUSIP NO. 372430 10 8 13G PAGE 5 of 8 PAGES
--------- ---------------------------------------------------------------------
1 NAME OF REPORTING PERSON:
BVF INC.
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):
--------- ---------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) |X| (b) |_|
--------- ----------------------------------------------------------------------
3 SEC USE ONLY
--------- ----------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
DELAWARE
--------- ---------------- ----- -----------------------------------------------
NUMBER SOLE VOTING POWER
OF 5 0
SHARES -----------------------------------------------
BENEFICIALLY SHARED VOTING POWER
OWNED BY EACH 6 1,451,400
REPORTING -----------------------------------------------
PERSON SOLE DISPOSITIVE POWER
WITH 7 0
-----------------------------------------------
SHARED DISPOSITIVE POWER
8 1,451,400
--------- ----------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,451,400
--------- ----------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES* |_|
--------- ----------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
6.5%
--------- ----------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
IA, CO
--------- ----------------------------------------------------------------------
* SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
CUSIP NO. 372430 10 8 13G PAGE 6 of 8 PAGES
ITEM 1(a). NAME OF ISSUER:
Genome Therapeutics Corp. ("Genome")
ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
100 Beaver Street
Waltham, Massachusetts 02154
ITEM 2(a). NAME OF PERSON FILING:
This Schedule 13G is being filed on behalf of the following
persons* (the "Reporting Persons"):
(i) Biotechnology Value Fund, L.P. ("BVF")
(ii) Biotechnology Value Fund II, L.P. ("BVF2")
(iii) BVF Partners L.P. ("Partners")
(iv) BVF Inc. ("BVF Inc.")
* Attached as Exhibit 1 is a copy of an agreement among
the Reporting Persons filing (as specified
hereinabove) that this Schedule 13G is being filed on
behalf of each of them.
ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE:
The principal business office of the Reporting Persons
comprising the group filing this Schedule 13G is located at 227 West Monroe
Street, Suite 4800, Chicago, Illinois, 60606.
ITEM 2(c). CITIZENSHIP:
BVF: a Delaware limited partnership
BVF2: a Delaware limited partnership
Partners: a Delaware limited partnership
BVF Inc.: a Delaware corporation
ITEM 2(d). TITLE OF CLASS OF SECURITIES:
Common Stock, $0.10 par value.
ITEM 2(e). CUSIP NUMBER:
372430 10 8
<PAGE>
CUSIP NO. 372430 10 8 13G PAGE 7 of 8 PAGES
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13d-1(b), OR
13d-2(b) OR (c) CHECK WHETHER THE PERSON FILING IS: ONE OF
THE FOLLOWING
Not applicable as this Schedule 13G is filed pursuant to Rule
13d-1(c).
ITEM 4. OWNERSHIP:
The information in items 1 and 5 through 11 on the cover pages
(pp. 2 - 5) on this Schedule 13G is hereby incorporated by reference.
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
If this statement is being filed to report the fact that as of
the date hereof the Reporting Persons have ceased to be the beneficial owner of
more than five percent of the class of securities check the following. |_|
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER
PERSON:
BVF shares voting and dispositive power over the shares of the
common stock it beneficially owns with Partners. BVF2 also shares voting and
dispositive power over the shares of the common stock it beneficially owns with
Partners. Partners and BVF Inc. share voting and dispositive power over the
shares of the common stock they beneficially own with, in addition to BVF and
BVF2, certain managed accounts on whose behalf Partners, as investment manager,
purchased such shares. None of the managed accounts individually owns more than
5% of the common stock of Genome.
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH
ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING
COMPANY:
Not applicable.
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF A GROUP:
Not applicable.
ITEM 9. NOTICE OF DISSOLUTION OF GROUP:
Not applicable.
<PAGE>
CUSIP NO. 372430 10 8 13G PAGE 8 of 8 PAGES
ITEM 10. CERTIFICATION
By signing below I certify that, to the best of my knowledge
and belief, the securities referred to above were not acquired and are not held
for the purpose of or with the effect of changing or influencing the control of
the issuer of the securities and were not acquired and are not held in
connection with or as a participant in any transaction having that purpose or
effect.
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true,
complete and correct.
Dated: December 11, 2000
BIOTECHNOLOGY VALUE FUND, L.P.
By: BVF Partners L.P., its general partner
By: BVF Inc., its general partner
By: /s/ Mark N. Lampert
------------------------------------
Mark N. Lampert
President
BIOTECHNOLOGY VALUE FUND II, L.P.
By: BVF Partners L.P., its general partner
By: BVF Inc., its general partner
By /s/ Mark N. Lampert
------------------------------------
Mark N. Lampert
President
BVF PARTNERS L.P.
By: BVF Inc., its general partner
By: /s/ Mark N. Lampert
-------------------------------------
Mark N. Lampert
President
BVF INC.
By: /s/ Mark N. Lampert
------------------------------------
Mark N. Lampert
President
